Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation–Associated Inherited Retinal Dystrophy
2019276 citationsAlbert M. Maguire, Stephen R. Russell et al.Ophthalmologyprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of Amy Tillman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Tillman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Tillman more than expected).
This network shows the impact of papers produced by Amy Tillman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Tillman. The network helps show where Amy Tillman may publish in the future.
Co-authorship network of co-authors of Amy Tillman
This figure shows the co-authorship network connecting the top 25 collaborators of Amy Tillman.
A scholar is included among the top collaborators of Amy Tillman based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Amy Tillman. Amy Tillman is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Maguire, Albert M., Stephen R. Russell, Jennifer Wellman, et al.. (2019). Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation–Associated Inherited Retinal Dystrophy. Ophthalmology. 126(9). 1273–1285.276 indexed citations breakdown →
Russell, Stephen R., Jean Bennett, Jennifer Wellman, et al.. (2018). Three-year update for the phase 3 voretigene neparvovec study in biallelic RPE65 mutation–associated inherited retinal disease. Investigative Ophthalmology & Visual Science. 59(9). 3900–3900.2 indexed citations
7.
Chung, Daniel C., Stephen R. Russell, Jean Bennett, et al.. (2017). Correlation of multi-luminance mobility testing with visual function tests in a phase 3 trial of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease. Investigative Ophthalmology & Visual Science. 58(8). 3292–3292.3 indexed citations
8.
Russell, Stephen R., Jean Bennett, Jennifer Wellman, et al.. (2017). Year 2 results for a phase 3 trial of voretigene neparvovec in biallelic RPE65-mediated inherited retinal disease. Investigative Ophthalmology & Visual Science. 58(8). 4122–4122.6 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.